Disclosure Of Interests In Other Entities [Text Block]

Egetis Therapeutics - Filing #5995613

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31
Disclosure of interests in other entities [text block]	—	NOT 21	—	—	—	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	—	—	3,801,000,000 SEK	—	—	—	—	—	—	3,459,000,000 SEK	—	—	—
Non-current assets	—	—	4,122,000,000 SEK	—	—	—	—	—	—	4,143,000,000 SEK	—	—	—
Current liabilities	—	—	2,042,000,000 SEK	—	—	—	—	—	—	1,039,000,000 SEK	—	—	—
Non-current liabilities	—	—	952,000,000 SEK	—	—	—	—	—	—	1,108,000,000 SEK	—	—	—
Profit (loss)	—	3,436,000,000 SEK	—	—	—	—	—	—	3,269,000,000 SEK	—	—	—	—
Comprehensive income	- SEK	3,435,000,000 SEK	—	- SEK	- SEK	3,435,000,000 SEK	- SEK	- SEK	3,270,000,000 SEK	—	3,270,000,000 SEK	- SEK	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Other comprehensive income	—	1,000,000 SEK	—	—	—	—	—	—	1,000,000 SEK	—	—	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	—	—	3,510,000,000 SEK	—	—	—	—	—	—	3,033,000,000 SEK	—	—	1,277,000,000 SEK
Tax expense (income)	—	3,000,000 SEK	—	—	—	—	—	—	1,000,000 SEK	—	—	—	—